Autopsy report · NCT01631643

One Touch® Verio®IQ European Clinical Outcomes Study

“Business decision to withdraw trial”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 4

Sponsor

LifeScan

Sponsor type

Industry

Conditions

Diabetes

Interventions

One Touch VerioIQ Blood Glucose Monitor

Participants

0

Trials that died the same way

• Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)
  “Company decision to discontinue trial” (85% match in meaning)
• A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia
  “Trial terminated early per business decision” (78% match in meaning)
• A Prospective Longitudinal Collection of Subjects Diagnosed With Small Cell Lung Cancer
  “Decision was made by Sponsor to stop the trial.” (72% match in meaning)
• Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7
  “The trial ended earlier than planned due to slow enrolment, which has made it unfeasible to achieve the target sample size within a reasonable timeframe. Consequently, a business decision has been made to discontinue funding for the trial.” (70% match in meaning)
• Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
  “Trial terminated due to business decision, not based on any safety or efficacy concerns.” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.